DAOA and schizophrenia: The relative specificity of DAO or DAOA polymorphisms in combination with brain functional connectivity alterations or other risk genetic variants for schizophrenia and the ongoing development of more selective and potent oxidase inhibitory agents may open novel possible future directions in both diagnosis and treatment of psychotic disorders, driving to a theranostic innovation in the psychiatric field too.